The novelty of our strategy for finding biomarkers for MSA and PD is the simultaneous quantification of SYN and TPPP and the calculation of the ratio of these quantities, which may allow distinctions to be made not only between patients and controls, but also between MSA and PD. This evidence concerns the gene TPPP and Parkinson disease.